111 related articles for article (PubMed ID: 36342355)
1. Nutlin-3 acts as a DNA methyltransferase inhibitor to sensitize esophageal cancer to chemoradiation.
Chang WL; Hsieh CH; Kuo IY; Lin CH; Huang YL; Wang YC
Mol Carcinog; 2023 Feb; 62(2):277-287. PubMed ID: 36342355
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
[TBL] [Abstract][Full Text] [Related]
3. Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma.
Ito K; Ishida H; Fujishima F; Nakamura Y; Konno T; Ise K; Hata S; Ozawa Y; Taniyama Y; Kamei T; Sasano H
Anticancer Res; 2022 Jun; 42(6):2875-2882. PubMed ID: 35641284
[TBL] [Abstract][Full Text] [Related]
4. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
Chen Y; Xin H; Peng H; Shi Q; Li M; Yu J; Tian Y; Han X; Chen X; Zheng Y; Li J; Yang Z; Yang L; Hu J; Huang X; Liu Z; Huang X; Zhou H; Cui X; Li F
Cancer Res; 2020 Jun; 80(11):2175-2189. PubMed ID: 32066565
[TBL] [Abstract][Full Text] [Related]
6. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.
Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC
J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052
[TBL] [Abstract][Full Text] [Related]
7. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer.
Tang YA; Lin RK; Tsai YT; Hsu HS; Yang YC; Chen CY; Wang YC
Clin Cancer Res; 2012 Aug; 18(16):4325-33. PubMed ID: 22733537
[TBL] [Abstract][Full Text] [Related]
8. Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity.
Zhang W; Yan W; Qian N; Han Q; Zhang W; Dai G
Chin Med J (Engl); 2022 Feb; 135(5):606-618. PubMed ID: 35191417
[TBL] [Abstract][Full Text] [Related]
9. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
10. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
[TBL] [Abstract][Full Text] [Related]
11. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
13. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
14. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
15. FAM3B promotes progression of oesophageal carcinoma via regulating the AKT-MDM2-p53 signalling axis and the epithelial-mesenchymal transition.
He SL; Wang WP; Yang YS; Li EM; Xu LY; Chen LQ
J Cell Mol Med; 2019 Feb; 23(2):1375-1385. PubMed ID: 30565387
[TBL] [Abstract][Full Text] [Related]
16. Linc-ROR regulates apoptosis in esophageal squamous cell carcinoma via modulation of p53 ubiquitination by targeting miR-204-5p/MDM2.
Gao H; Wang T; Zhang P; Shang M; Gao Z; Yang F; Liu R
J Cell Physiol; 2020 Mar; 235(3):2325-2335. PubMed ID: 31541467
[TBL] [Abstract][Full Text] [Related]
17. microRNA-377 acts as a suppressor in esophageal squamous cell carcinoma through CBX3-dependent P53/P21 pathway.
He Z; Chen J; Chen X; Wang H; Tang L; Han C
J Cell Physiol; 2021 Jan; 236(1):107-120. PubMed ID: 33459391
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
19. Diclofenac exhibits cytotoxic activity associated with metabolic alterations and p53 induction in ESCC cell lines and decreases ESCC tumor burden in vivo.
Kabir MF; Jackson JL; Fuller AD; Gathuka L; Karami AL; Conde DG; Klochkova A; Mu A; Cai KQ; Klein-Szanto AJ; Muir AB; Whelan KA
Carcinogenesis; 2023 May; 44(2):182-195. PubMed ID: 37014121
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
